Drugs / INO-3112
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02172911 | Jun 2014 → Sep 2017 | cervical cancer | Inovio Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-01-04 | Inovio Pharmaceuticals | INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) inovio.com ↗ |
| 2024-01-04 | Coherus Oncology, Inc. | INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) coherus.com ↗ |
| 2016-11-14 | Inovio Pharmaceuticals | Inovio’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer inovio.com ↗ |
| 2016-03-29 | Inovio Pharmaceuticals | Inovio Updates INO-3112 HPV Immunotherapy Development Plan inovio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-3112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02172911 ↗ |
| Modality | Vaccine | “INO-3112 DNA vaccines” NCT02172911 ↗ |
| Route | Intramuscular | “1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered” NCT02172911 ↗ |